5-HT3 receptors: A review of their pharmacologic and therapeutic aspects

Drugs of Today

Volumn 32, Issue 7, 1996, Pages 515-528

  Kulkarni, S K ^a   Roychoudhury, M ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BEMESETRON; CISPLATIN; DOLASETRON MESILATE; GRANISETRON; METOCLOPRAMIDE; ONDANSETRON; RECEPTOR SUBTYPE; SEROTONIN 3 AGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; TROPISETRON; ZACOPRIDE; ZATOSETRON;

ANXIETY; BEHAVIOR; BRAIN; CHEMOTHERAPY; DRUG ABUSE; HISTOCHEMISTRY; HUMAN; MEMORY; NAUSEA; NONHUMAN; PSYCHOSIS; REVIEW; SEROTONINERGIC SYSTEM; VOMITING; WITHDRAWAL SYNDROME;

EID: 0029772022     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (161)

1. Stevens, L.T., Lee, F.S. Action of intermittent pressure and of defibrinated blood upon blood vessels of frog and terrapin. Johns Hopkins Biol Studies 1884, 3: 99.
2. Brodie, T.G. The immediate action of an intravenous injection of blood serum. J Physiol 1990, 26: 48-71.
3. Vialli, M., Erspamer, V. Cellule enterocromaffini e cellule basigranulose acidofile nei vertebrati. Z Zelstorsch Mikrosk Anat 1933, 19: 743.
4. Rapport, M.M., Green, A.A., Page, I. Purification of the substance which is responsible for baso-constrictor activity of serum. Fed Proc 1947, 6: 184.
5. Rapport, M.M., Green, A.A., Page, I.H. Serum vasoconstrictor (serotonin): Isolation and characterization. J Biol Chem 1948, 176: 1243-51.
6. Rapport, M.M. Serum vasoconstrictor (serotonin): Presence of creatinine in the complex. A proposed structure of the vasoconstrictor principle. J Biol Chem 1949, 180: 961-9.
7. Hamlin, K.E., Fisher, F.E. The synthesis of 5-hydroxytryptamine. J Am Chem Soc 1951, 73: 5007-8.
8. Bogdanski, D.F., Pletscher, A., Brodie, B.B., Undenfriend, S. Identification and assay of serotonin in brain. J Pharmacol Exp Ther 1956, 117: 88-98.
9. Brodie, T.G., Shore, P.A. A concept for a role of serotonin and norepinephrine as chemical mediators in the brain. Ann NY Acad Sci 1957, 66: 631-42.
10. Erspamer, V. Occurrence of indolealkylamines in nature. In: 5-Hydroxytryptamine and Related Indolealkylamines. Erspamer, V. (Ed.). Handbook of Experimental Pharmacology. Springer-Verlag: Berlin 1966, 19: 132-81.
11. Essman, W.B. Serotonin distribution in tissues and fluids. In: Availability, Localisation, and Disposition, Vol. 1. Serotonin in Health and Disease. Essman, W.B. (Ed.). Spectrum Publications, Inc.: New York 1978, 15-179.
12. Koella, W.P. Serotonin and sleep. In: Neuronal Serotonin. Osborne, N.N., Hamon, M. (Eds.). John Wiley: New York 1988, 153-70.
13. Myers, R.D. Serotonin and thermoregulation: Old and new views. J Physiol 1981, 77: 505-13.
14. McEntee, W.J., Crook, T.H. Serotonin, memory and the aging brain. Psychopharmacology 1991, 103: 143-9.
15. Richardson, B.P. Serotonin and nociception. Ann NY Acad Sci 1990, 600: 511-20.
16. Di Chiara, G., Camba, G., Spano, P.F. Evidence for inhibition by brain serotonin of mouse killing behaviour in rats. Nature 1971, 233: 272-3.
17. Gorzalka, B.B., Mendelson, S.D., Watson, N.V. Serotonin receptor subtypes and sexual behaviour. Ann NY Acad Sci 1990, 600: 435-45.
18. Curzon, G. Serotonin and appetite. Ann NY Acad Sci 1990, 600: 521-31.
19. Van de Kar, L. D. Neuroendocrine pharmacology of serotonergic neurons. Annu Rev Pharmacol Toxicol 1991, 31: 289-320.
20. Sternbach, H. The serotonin syndrome. Am J Psychiatry 1991, 148: 705-13.
21. Wesemann, W., Weiner, N. Circadian rhythm of serotonin binding in rat brain. Prog Neurobiol 1990, 35: 405-28.
22. Hollenberg, N.K. Serotonin and vascular responses. Annu Rev Pharmacol Toxicol 1988, 28: 41-59.
23. Parsons, A.A. 5-HT receptors in human and animal cerebrovasculature. TIPS 1991, 21: 310-5.
24. Nutt, D.J., George, D.T. Serotonin and anxiety. Neurobiol Anxiety 1990, 3: 189-221.
25. Meltzer, H.Y. Role of serotonin in depression. Ann NY Acad Sci 1990, 600: 486-99.
26. Sheeham, D.V., Zak, J.P., Miller, J.A., Fanous, B.S.L. Panic disorder: The potential role of serotonin reuptake inhibitors. J Clin Psychiatry 1988, 49 (Suppl.): 30-6.
27. Insel, T.R., Zohar, J., Benkelfat, C., Murphy, D.L. Serotonin in obsessions, compulsions, and the control of aggressive impulses. Ann NY Acad Sci 1990, 600: 574-86.
28. Csernansky, J.G., Poscher, M., Faull, K.F. Sertonin (5-HT) in schizophrenia. In: Serotonin in Major Psychiatric Disorders. Coccaro, E.F., Murphy, D.L. (Eds.). Am Psychiat Press: Washington, DC 1992.
29. Mann, J.J., Arango, V., Underwood, M.D. Serotonin and suicidal behaviour. Ann NY Acad Sci 1990, 600: 476-85.
30. Humphrey, P.P.A., Feniuk, W., Perren, M.J., Beresford, I.J.M., Skingle, M., Whalley, E.T. Serotonin and migraine. Ann NY Acad Sci 1990, 600: 587-600.
31. 3 receptor antagonists as antiemetics. TIPS 1992, 12: 46-8.
32. Sellers, E.M., Higgins, G.A., Sabell, M.B. 5-HT and alcohol abuse. TIPS 1992, 13: 69-75.
33. Gleerup, G., Persson, B , Hedner, T. Serotonin-induced platelet aggregation predicts the anti-hypertensive response to serotonin receptor antagonists. Eur J Clin Pharmacol 1993, 44: 221-5.
34. Cross, A.J. Serotonin in Alzheimer-type dementia and other dementing illnesses. Ann NY Acad Sci 1990, 600: 405-17.
35. 2 antagonist on Parkinsonism rest tremor. Curr Ther Res 1987, 41: 298-300.
36. Cross, A.J. Serotonin in neurodegenerative disorders. In: Neuronal Serotonin. Osborne, N.N., Hamon, M. (Eds.). John Wiley: New York 1988, 231-45.
37. Gaddum, J.H., Picarelii, Z.P. Two kinds of tryptamine receptors. Br J Pharmacol 1957, 12: 323-8.
38. Humphrey, P.P.A., Hartig, P., Hoyer, D. A proposed new nomenclature for 5-HT receptors. TIPS 1993, 14: 233-6.
39. Hoyer, D., Clarke, D.E., Fozard, J.R. et al. VII International Union of Pharmacology Classification of Receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994, 46 (2): 157-203.
40. Bockaert, J. Serotonin receptors: From genes to pathology. In: Critical Issues in the Treatment of Affective Disorders. Langer, S.Z., Brunello, N., Racagni, G., Mendlewicz, J. (Eds.). Karger: Basel 1994, 9: 1-8.
41. Fozard, J.R., Mwaluko, G.M.P. The stimulant response of 5-hydroxytryptamine on cardiac sympathetic nerves: Resistance to blockade by classical tryptamine receptor antagonists. 6th Int Cong Pharmacol (July, Helsinki) 1975, Abst 697.
42. Fozard, J.R., Mwaluko, G.M.P. Mechanism of the indirect sympathomimetic effect of 5-hydroxytryptamine on the isolated heart of the rabbit. Br J Pharmacol 1976, 57: 115-25.
43. Fozard, J.R., Mobarok Ali, A.R.M. Receptors for 5-hydroxytryptamine on the synpathetic nerves of the rabbit heart. Naunyn-Schmied Arch Pharmacol 1978, 301: 223-35.
44. 3 receptor antagonists. In: The Peripheral Actions of 5-Hydroxytryptamine. Fozard, J.R. (Ed.). Oxford Medical Publications: Oxford 1989, 354-76.
45. Fozard, J.R. MDL 72222, a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn-Schmied Arch Pharmacol 1984, 326: 36-44.
46. Richardson, B.P., Engel, G., Donatsch, P., Stadler, P.A. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 1985, 316: 126-31.
47. 3 receptor antagonist. Br J Pharmacol 1987, 90: 87P.
48. 3 antagonist. J Pharm Pharmacol 1988, 40: 301-2.
49. Wallis, D.I. Interaction of 5-hydroxytryptamine with autonomie and sensory neurones. In: The Peripheral Actions of 5-Hydroxytryptamine. Fozard, J.R. (Ed.). Oxford Medical Publications: Oxford 1989, 220-46.
50. Gershon, M.D., Mawe, G.M., Branchek, T.A. 5-Hydroxytryptamine and enteric neurones. In: The Peripheral Actions of 5-Hydroxytryptamine. Fozard, J.E. (Ed.). Oxford Medical Publications: Oxford 1989, 247-73.
51. Bradley, P.B., Engel, G., Feniuk, W. et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 1986, 25: 563-76.
52. 3 receptors in mammalian hindbrain. TIPS 1990, 1: 135-7.
53. 3H]-GR65630 in rat brain using quantitative autoradiography. Neurosci Lett 1988, 94: 156-60.
54. 3H]-ICS 205-930. Neuroscience 1989, 31: 393-400.
55. 3H]-(S)-zacopride. Neuropharmacology 1990, 29: 1037-45.
56. 3H]-quipazine in rodent brain. Eur J Pharmacol 1990, 187: 75-85.
57. 3 recognition sites in human brain tissue. J Neurochem 1989, 53: 1787-93.
58. 3H]-GR65630 to rat area postrema, vagus nerve and brains of several species. Eur J Pharmacol 1989, 159: 157-64.
59. 3 receptors in postmortem brains of normal and schizophrenic subjects. Soc Neurosci Abst 1991, 287: 11.
60. Fozard, J.R. Neuronal 5-HT receptor in the periphery. Neuropharmacology 1984, 23: 1473-86.
61. 1C receptor-mediated stimulation of inositol phosphate production in pig choroid plexus: A pharmacological characterization. Naunyn-Schmied Arch Pharmacol 1989, 339: 252-8.
62. 62. McQueen, D.A., Mir, A.K. 5-Hydroxytryptamine and cardiopulmonary and carotid body reflex mechanisms. In: The Peripheral Actions of 5-Hydroxytryptamine. Fozard, J.R. (Ed.). Oxford University Press: Oxford 1989, 301-26.
63. 3 receptor-mediated electrical responses in nodose ganglion neurones and clonal neuroblastoma cells maintained in culture. In: Serotonin: Molecular Biology, Receptors and Functional Effects. Fozard, J.R., Saxena, P.R. (Eds.). Birkhauser Verlag: Basel 1991, 84-94.
64. Wallis, D.I., Elliot, P. The electrophysiology of 5-HT. In: Serotonin: Molecular Biology, Receptors and Functional Effects. Fozard, J.R., Saxena, P.R. (Eds.). Birkhauser Verlag: Basel 1991, 203-19.
65. Zifa, E., Fillion, G. 5-Hydroxytryptamine receptors. Pharmacol Rev 1992, 44 (3): 402-58.
66. 3 recognition sites in membranes of NIE-115 neuroblastoma cells by radioligand binding. Mol Pharmacol 1988, 33: 303-9.
67. 3 recognition sites by radioligand binding in NG-108-15 neuroblastoma-glioma cells. Eur J Pharmacol 1987, 143: 291-2.
68. 3H]-ICS-205-930. Naunyn-Schmeid Arch Pharmacol 1988, 337: 493-9.
69. 3 binding sites in the rat cerebral cortex and NG-108-15 clonal cells. Biochem Pharmacol 1990, 40: 1541-50.
70. 3-like receptors in the rat medial prefrontal cortex: Biochemical and electrophysiological studies. Eur J Pharmacol 1990, 183: 1958-9.
71. 3 receptors are membrane ion channels. Nature 1989, 339: 706-9.
72. Trendleburg, U. Pharmacology of autonomie ganglia. Annu Rev Pharmacol 1961, 1: 219-38.
73. Gyermek, L., Bindler, E. Action of indole alkylamines and amidines on the inferior mesenteric ganglion of the cat. J Pharmacol Exp Ther 1962, 138: 159-64.
74. 3 receptor-mediated electrical response in cultured mouse neuroblastoma cells. Neuropharmacology 1988, 27: 301-7.
75. Changeux, I.P., Giraudot, J., Dennis, M. The nicotine acetylcholine receptor, molecular architecture of a ligand-regulated ion channel. TIPS 1987, 8: 465-72.
76. 3 receptor. Brain Res 1995, 533: 46-52.
77. 3 binding sites solubilized from membranes of NG-108-15 neuroblastoma-glioma cells. J Neurochem 1990, 55: 1526-36.
78. Humphrey, P.P.A., Richardson, B.P. Classification of 5-HT receptors and binding sites, and overview. In: Serotonin, Actions, Receptors, Pathophysiology. Mylechrane, E.J., Angus, J.A., de La Lande, I.S., Humphrey, RRA. (Eds.). Proceedings of a Satellite Symposium of the IUPHAR 10th International Congress of Pharmacology (Sept 4-6, Heron Island). Macmillan: London 1987.
79. 3H-quipazine in the CNS. Naunyn-Schmied Arch Pharmacol 1989, 338: 472-5.
80. 3 recognition sites: Fact or artifact. Eur J Pharmacol 1989, 171: 137-9.
81. 3 binding sites. Eur J Pharmacol 1989, 168: 355-62.
82. 3H]-RS-42358-197: Evidence for receptor heterogeneity. J Neurochem 1993, 61: 1927-32.
83. 3 receptors. J Neurochem 1995, 65(1): 104-10.
84. Galzin, A.M., Langer, S.Z. Modulation of 5-HT release by presynaptic inhibitory and facilitator/ 5-HT receptors in brain slices. Adv Biosci 1991, 82: 59-62.
85. Feuerstein, T.J., Hertig, G. Serotonin enhances hippocampal noradrenaline release: Evidence for facilitatory 5-HT receptors within the CNS. Naunyn-Schmied Arch Pharmacol 1986, 333: 191-7.
86. Blandina, P., Goldfarb, J., Walcott, J., Green, J.P. Serotonergic modulation of the release of endogenous norepinephrine from rat hypothalamic slices. J Pharmacol Exp Ther 1991, 256: 341-7.
87. 3 receptor antagonist GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 1987, 92: 881-94.
88. 3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the rat. Br J Pharmacol 1990, 99: 227-32.
89. 3 receptors mediate inhibition of acetylcholine release in cortical tissue. Nature 1989, 338: 762-3.
90. 3H]-GABA from slices of rat caudate-putamen. Eur J Pharmacol 1991, 196: 189-95.
91. 3H]-GABA release from guinea-pig hippocampal synaptosomes. Fundam Clin Pharmacol 1990, 4: 566.
92. Wallis, D.I., Nash, H.L. The action of methylated derivatives of 5-hydroxytryptamine at ganglionic receptors. Neuropharmacology 1980, 19: 465-72.
93. Ireland, S.J., Tyers, M.B. Pharmacological characterisation of 5-hydroxytryptamine-induced depolarisation of the rat isolated vagus nerve. Br J Pharmacol 1987, 90: 229-38.
94. Fastier, F.N. Structure-activity relationships of amidine derivatives. Pharmacol Rev 1962, 14: 37-90.
95. 3 receptor agonist. Eur J Pharmacol 1990, 182: 193-7.
96. Sanger, G.J., Nelson, D.R. Selective and functional 5-hydroxytryptamine-3 receptor antagonism by BRL 43694 (granisetron). Eur J Pharmacol 1989, 159: 113-24.
97. 3 receptors. In: Neuronal Serotonin. Osborne, N.N., Hamon, M. (Eds.). John Wiley: New York 1988, 465-506.
98. 3 receptor antagonist: Synthesis and structure-activity relationships, J Med Chem 1992, 35: 310-9.
99. 3 receptors. Br J Pharmacol 1988, 94: 397-412.
100. Kovac, A.L. Use of serotonin receptor antagonists in the prevention and treatment of nausea and vomiting. Hosp Formulary 1992, 28: 988-98.
101. 3 receptor antagonists. Drugs 1991, 42: 551-68.
102. Beck, T.M., Hesketh, P.J., Madajewicz, S., Navari, R.M. Stratified randomized, double-blind comparison of i.v. ondansetron. J Clin Oncol 1992, 10: 1969-75.
103. 3 receptor antagonists and anti-emetic mechanisms of action. Anticancer Drugs 1992, 3: 79-85.
104. Gidda, J.S., Evans, D.C., Cohen, M.L., Wong, D.T., Robertson, D.W., Parli, C.J. Antagonism of serotonin (5-HT) receptors within the blood-brain barrior prevents cisplatin-induced emesis in dogs. J Pharmacol Exp Ther 1995, 273: 695-701.
105. Rolia, F., De Angelis, V., Cognetti, F. et al. Ondansetron vs. granisetron, both combined with descamethasone in the prevention of cisplatin-induced emesis. Proc Am Soc Clin Oncol 1995, 14: 523.
106. 3 receptor antagonist, GR 38032F responses to injection of a neurokinin agonist into the ventral tegmental area of rat brain. Eur J Pharmacol 1987, 138: 303-5.
107. 3 antagonists ondansetron. J Psychopharmacol 1992, 6: 110.
108. Inverson, S.D. 5-HT and anxiety. Neuropharmacology 1984, 23: 1553-60.
109. 3 receptors in the rat brain using radioligand binding. Nature 1987, 330: 746-8.
110. Gleeson, S., Ahlers, S.T., Mansbackm R.S., Foust, J.M., Barrett, J.E. Behavioural studies with anxiolytic drugs VI. Effect on punished responding of drugs interacting with serotonin receptor subtypes. J Pharmacol Exp Ther 1989, 250 (3): 809-17.
111. 3 receptor antagonists. Pharmacol Toxicol 1992, 70: 157-62.
112. 3 receptors. Pharmacol Ther 1990, 47: 181-202.
113. 3 antagonists in the social interaction and elevated plus maze tests of anxiety in the rat. Psychopharmacology 1989, 99: 248-51.
114. 3 antagonists GR 38032F and BHL 24924 on anxiety in socially isolated rats. Br J Pharmacol 1989, 97: 457P.
115. 3 receptor antagonists, ondansetron and WAY 100289, in the elevated plus maze test of anxiety of mice. Psychopharmacology 1995, 117: 306-12.
116. Costall, B., Jones, B.J., Kelly, M.E. et al. The effects of ondansetron (GR 38032F) in rat and mice treated subchronically with diazepam. Pharmacol Biochem Behav 1989, 34: 769-78.
117. 3 Antagonist, in the Treatment of Psychiatric Disorders. 5th World Cong Biol Psychiatry (June, Florence) 1991, 17-9.
118. Mele, P.E., McDonough, J.R., McLean, D.B., O'Halloran, K.P. Cisplatin-induced conditioned taste aversion: Attenuation by dexamethasone but not zacopride or GR 38032F. Eur J Pharmacol 1992, 218: 229-36.
119. Costall, B., Jones, B.J., Kelly, M.E., Naylor, R.J., Onaivi, E.S., Tyers, M.B. Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse. Pharmacol Biochem Behav 1990, 36: 339-44.
120. 3 antagonist GR 38032F (ondansetron) on benzodiazepine withdrawal in rats. Eur J Pharmacol 1990, 185: 179-86.
121. Prather, P.L., Rezazadeh, S.M., Lane, J.D. et al. Conflicting evidence regarding the efficacy of ondansetron in benzodiazepine withdrawal. J Pharmacol Exp Ther 1993, 264 (2): 622-30.
122. 3 receptor antagonists block morphine-and nicotine- but not amphetamine-induced reward. Psychopharmacology 1989, 97: 175-8.
123. Mucha, R.G., Van der Kooy, D., O'Shaugnessy, M., Bucenicks, P. Drug reinforcement studied by the use of place preference conditioning in rat. Brain Res 1982, 243: 91-105.
124. Cooper, S.J. Interactions between endogenous opioids and dopamine. Implications for reward and aversion. In: The Mesolimbic Dopamine System: From Motivation to Action. Willner, P., Scheel-Kruger, J. (Eds.). John Wiley: Chichester 1991, 331-66.
125. Di Chiara, G., Imperato, A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988, 85: 5274-8.
126. 3 antagonists block behavioural effects of ethanol. 5th ISBRA Congress (Toronto) 1990, 45.
127. 3 receptors antagonists on behavioural indices of morphine reward and withdrawal. Br J Pharmacol 1991, 102(Suppl.): 144P.
128. 3 receptors control dopamine release in the nucleus accumbens of freely moving rats. Neurosci Lett 1989, 101: 214.
129. 3 antagonist, reduces cocaine's psychomotor stimulant effects in the rat. Psychopharmacology 1990, 101: 559.
130. Oakley, N.M., Jones, B.J., Tyers, M.B., Costall, B., Domeney, A.M. The effect of GR 38032F on alcohol consumption in the marmoset. Br J Pharmacol 1988, 95: 870P.
131. 3 antagonist GR 38032F decreases alcohol consumption in rats. Soc Neurosci Abst 1988, 21: 4.
132. 3 antagonist ondansetron in addictive disorders. 5th World Cong Biol Psychiatry (June, Florence) 1991, 29-31.
133. 3 receptor mediated ion current in NCB-20 neuroblastoma cells. Neurosci Lett 1991, 122: 57-60.
134. Barry, J.M., Costall, B., Kelly, M.E., Naylor, R.J. Withdrawal syndrome following subchronic treatment with anxiolytic agents. Pharmacol Biochem Behav 1987, 27: 239-45.
135. Costall, B., Jones, B.J., Kelly, M.E., Naylor, R.J., Onaivi, E.S., Tyers, M.B. Sites of action of ondansetron to inhibit withdrawal from drugs of abuse. Pharmacol Biochem Behav 1990, 36: 97-104.
136. Altman, H.J., Normile, H.J., Gershon, S. Non-cholinergic pharmacology in human cognitive disorders. In: Cognitive Neurochemistry. Stahl, S.M., Iversen, S.D., Goddman, E.L. (Eds.). Oxford University Press: Oxford 1987, 346-71.
137. 3 receptor antagonist, on cognition in rodents and primates. Pharmacol Biochem Behav 1990, 35 (4): 955-62.
138. 3 receptor antagonists. Pharmacol Biochem Behav 1990, 37: 717-27.
139. Domeney, A.M., Costall, B., Gerrard, P.A., Jones, D.N.C., Naylor, R.J., Tyers, M.B. The effect of ondansetron on cognitive performance in the marmoset. Pharmacol Biochem Behav 1991, 38: 169-75.
140. Fontana, D.J., Daniels, S.E., Henderson, C., Eglen, R.M., Wong, E.H.F. Ondansetron improves cognitive performance in the Morris water maze spatial navigation task. Psychopharmacology 1995, 120: 409-17.
141. Von Frenckell, R., Ansseau, M., Wanthy, J. Effects of zacopride on vigilance, attention and memory. 17th Int Cong Neuropsychopharmacolog (Sept 10-14, Kyoto) 1992, 14-15.
142. 3 agonists decrease acetylcholine efflux from the cerebral cortex of freely-moving guinea-pigs. Br J Pharmacol 1990, 101: 448-52.
143. Bartus, R.T., Dean, R.L, Beer, B., Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217: 408-17.
144. Smith, R.J., Davies, L.F., Noble, J. The efficacy of zacopride in the prevention of scopolamine induced cognitive impairment in normal young volunteers. Proceedings of the Conference on Serotonin: From Cell Biology to Pharmacology and Therapeutics (March-April, Florence) 1989, 53.
145. Cooper, S.J. 5-HT and ingestive behaviour, In: Serotonin Receptors and Psychotropic Drugs. Marsden, C.A., Heal, D.J. (Eds.). Blackwell: Oxford 1991.
146. Fletcher, P.J. Increased food intake in satiated rats induced by 5-HT antagonists methysergide, metergoline and retanserine. Psychopharmacology 1988, 96: 237-42.
147. 1 receptors elicit feeding in satiated rats. Psychopharmacology 1989, 97: 54-8.
148. Fletcher, P.J., Davies, M. Effects of 8-OH-DPAT, buspirone and ICS 205-930 on feeding in a novel environment, comparisons with chlordiazepoxide and FG 7142. Psychopharmacology 1990, 102: 301-8.
149. 3 antagonist, ondansetron, on feeding and other behavioural responses. Br J Pharmacol 1990, 99: 237P.
150. Beczkowska, I.W., Bodnar, R.J. Naloxone and serotonin receptor subtype antagonists: Interactive effects upon deprivation induced intake. Pharmacol Biochem Behav 1991, 38: 605-10.
151. 3 receptor antagonist, reduces palatable food consumption in the non-deprived rat. Neuropharmacology 1994, 33 (6): 805-11.
152. Borowsky, B., Kuhn, C.M. Monoamine mediation of cocaine-induced hypothalamo-pituitary-adrenal activation. J Pharmacol Exp Ther 1991, 256: 204-10.
153. 3 receptor antagonists. III. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome. J Med Chem 1993, 36: 3286-92.
154. 3 receptor mediation is involved etiologically in the psychological stress lesion in the stomach of the mouse. J Pharmacol Exp Ther 1994, 271: 100-6.
155. 3 antagonist on carrageenin-induced hyperalgesia in rats. Pain 1989, 36: 249-55.
156. 3 receptor-mediated antinociception: Possible release of GABA. J Neurosci 1992, 11: 1881-8.
157. 3 receptor antagonist. Neurosci Lett 1988, 95: 313-7.
158. 3 receptor antagonists ADR-851 and ADR-882 in rats. Eur J Pharmacol 1991, 204: 117-9.
159. 3 antagonist, granisetron (BRL 43694), in the acute treatment of migraine headache. Headache 1991, 31: 296-7.
160. 3 receptor antagonist in a multicenter trial for acute migraine. Neuropharmacology 1994, 33: 509-13.
161. 3 receptor antagonists reverse helpless behaviour in rats. Eur J Pharmacol 1992, 212: 73-8.